Recombinant hCG versus Dual Triggering for final oocyte maturation in ICSI Cycles among Poor Responders with Endometriosis

Other OA: gold CC-BY-4.0
⚙ AI-generated summary by qwen3.7-flash, 2026-09-27 ⓘ

Among 152 poor responders with endometriosis undergoing ICSI, dual triggering of final oocyte maturation yielded more mature eggs and high-quality embryos with higher pregnancy rates than recombinant hCG alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Women with endometriosis often face difficulty becoming pregnant, mainly when their ovaries produce only a small number of eggs. In assisted fertility treatments, hormones are used to help eggs mature before they are collected. One common method uses a hormone called hCG, while another approach, known as dual triggering, combines hCG with an additional hormone to better mimic the body's natural process. In this study, we compared these two methods in 152 women with endometriosis and poor ovarian response undergoing fertility treatment. We found that women who received the two-hormone method produced more fully mature eggs, more good-quality embryos, and had higher chances of pregnancy than those who received hCG alone. These findings suggest that using both hormones may offer a better chance of success for some women with endometriosis undergoing fertility treatment and could help doctors tailor treatment to individual patient needs.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

organisms 1
noordeloos 2009062

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-11T06:07:16.930978+00:00
scilite
last seen: 2026-10-04T09:59:34.739275+00:00
unpaywall
last seen: 2026-09-26T06:30:31.687879+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine